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        Antigen-specifi  c approaches have been defi  ned 
that could prevent the development of type I 
diabetes (TID; for review see [  1  ]). However, 
antigen-driven strategies that could counter the 
disease at more advanced stages have yet to be 
defi  ned (  1  ). As with many autoimmune dis-
orders, TID most likely involves multiple auto-
antigens and diverse T cell specifi  cities (  2, 3  ). In 
addition, sequential spreading seems to orchestrate 
TID, with insulin being required for the initia-
tion of the disease (  4  ), whereas GAD-reactive 
T lymphocytes are more involved at later stages 
of TID (  5, 6  ). Thus, for an antigen-specifi  c 
therapy to be eff  ective and practical against TID, 
it would have to target late-stage epitopes that 
could counter diverse aggressive T cell speci-
fi  cities. GAD2 peptide corresponding to amino 
acid sequence 206  –  220 of GAD is considered 
a late-stage epitope because its T cell reactivity is 
detected at an advanced stage of the disease (  7  ). 
TCR transgenic T cells specifi  c for GAD2 pep-
tide were generated, but these produced both 
IFN      and IL-10 and were protective against 
TID when tested in a transfer model of passive 
diabetes (  8  ). Given this information, we rea-
soned that eff  ective presentation of GAD2 pep-
tide in vivo under noninfl  ammatory conditions 
would possibly induce IFN     - and IL-10  –  pro-
ducing T cells that could protect against TID. 
Because IFN      displays inhibitory activity against 
Th17 cells (  9, 10  ), the approach could prove 
eff  ective even at an advanced stage of the disease 
if Th17 cells play a pathogenic role in TID. To test 
these premises, GAD2 peptide was genetically 
inserted into the variable region of a heavy chain 
Ig gene, and the fusion gene was transfected into 
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  The role of Th17 cells in type I diabetes (TID) remains largely unknown. Glutamic acid 
decarboxylase (GAD) sequence 206  –  220 (designated GAD2) represents a late-stage epi-
tope, but GAD2-specifi  c T cell receptor transgenic T cells producing interferon      (IFN    ) 
protect against passive TID. Because IFN     is known to inhibit Th17 cells, effective presen-
tation of GAD2 peptide under noninfl  ammatory conditions may protect against TID at 
advanced disease stages. To test this premise, GAD2 was genetically incorporated into an 
immunoglobulin (Ig) molecule to magnify tolerance, and the resulting Ig-GAD2 was tested 
against TID at different stages of the disease. The fi  ndings indicated that Ig-GAD2 could 
not prevent TID at the preinsulitis phase, but delayed TID at the insulitis stage. More im-
portantly, Ig-GAD2 sustained both clearance of pancreatic cell infi  ltration and     -cell 
division and restored normoglycemia when given to hyperglycemic mice at the prediabetic 
stage. This was dependent on the induction of splenic IFN     that inhibited interleukin 
(IL)-17 production. In fact, neutralization of IFN     led to a signifi  cant increase in the frequency 
of Th17 cells, and the treatment became nonprotective. Thus, IFN     induced by an adjuvant 
free antigen, contrary to its usual infl  ammatory function, restores normoglycemia, most 
likely by localized bystander suppression of pathogenic IL-17  –  producing cells. 208 TARGETING TH17 CELLS FOR REVERSAL OF TYPE I DIABETES | Jain et al.
    RESULTS   
  Treatment with Ig-GAD2 restores normoglycemia 
  The I-A  g7    –  restricted diabetogenic GAD2 peptide was geneti-
cally expressed on an Ig molecule, and the resulting Ig-GAD2 
was used to test against TID. Similarly, the non  diabetogenic 
I-A  g7    –  restricted hen egg lysozyme (HEL) 11  –  25 sequence 
was also incorporated in an Ig, and the resulting Ig-HEL was 
used as control (  16  ). The chimeras were then tested for pre-
sentation to a GAD2-specifi  c T cell line. As indicated in   Fig. 1  , 
Ig-GAD2 was taken up by APCs, processed, and presented to 
GAD2-specifi  c T cells much more effi   ciently than free GAD2 
peptide (  Fig. 1 A, B  ).   The control Ig-HEL was unable to 
induce similar stimulation of the GAD2-specifi  c T cells. Ig-
GAD2 was then assayed for tolerogenic function by testing 
for prevention of TID in young NOD mice undergoing the 
initial phase of islet infi  ltration, which is referred to as the 
preinsulitis stage. The results in   Fig. 1 C   indicate that Ig-
GAD2 had no signifi  cant long-term protective eff  ect against 
TID relative to Ig-HEL or untreated mice. Knowing that 
insulin, but not GAD, is required for initiation of diabetes at 
the preinsulitis stage (  4  ), the lack of protection might have 
been caused by the absence of activated GAD2-specifi  c target 
T cells at this stage. We then tested Ig-GAD2 for suppression 
of diabetes at a later stage during insulitis. It has been shown 
that seroconversion to insulin autoantibody (IAA) production 
is indicative of ongoing insulitis (  17, 18  ), and our own studies 
indicated that among the 83% of female NOD mice that se-
roconvert to IAA at the age of 8  –  11 wk, 84% develop overt 
a myeloma B cell line along with the parental light chain gene 
for expression as a complete Ig-GAD2. Because Igs internalize 
into APCs via Fc      receptor (Fc     R), the grafted GAD2 pep-
tide will be effi   ciently dragged into the cells, where it accesses 
newly synthesized MHC class II molecules, and presenta-
tion will be signifi  cantly increased relative to free peptide, as 
was the case for other diabetogenic and encephalitogenic pep-
tides (  11  –  16  ). Moreover, because Igs are self-proteins, when 
injected into animals, presentation occurs without infl  amma-
tion, leading to lack of costimulation and magnifi  cation of 
tolerance (  12  –  14  ). 
  In an initial attempt, Ig-GAD2 was tested for prevention of 
TID before insulitis, but proved ineff  ective for delay of disease. 
However, when the treatment was administered at the insulitis 
stage, protection against TID was observed. More importantly, 
Ig-GAD2 given to hyperglycemic mice at the prediabetic stage 
was highly eff  ective, leading to clearance of pancreatic cell 
infi  ltration, stimulation of      -cell division, and restoration of 
normoglycemia. Investigation of the mechanism underlying 
reversal of disease revealed the presence of splenic IFN     -pro-
ducing GAD2-specifi  c T cells that were, indeed, responsible 
for reversal of disease because neutralization of IFN      restored 
progression to overt diabetes. In parallel, the protected mice 
had reduced production of IL-17 cells in the spleen and pan-
creas relative to diabetic mice, and exogenous IL-17 reinstated 
progression to diabetes in the otherwise protected animals. 
Thus, splenic IFN      likely interferes with supply of Th17 to the 
pancreas, leading to clearance of islet infi  ltration, stimulation of 
      cell division, and restoration of normoglycemia. 
    Figure 1.         Ig-GAD2 treatment given at the insulitis-positive stage 
reverses T1D.   (A and B) Presentation of Ig-GAD2 to T cells. NOD splenic 
APCs were incubated with free peptides (A) or Ig chimeras (B), and 1 h 
later GAD2-specific T cells were added. Activation was assessed by 
[  3  H]thymidine incorporation. HEL peptide and Ig-HEL were included as 
negative controls. (C and D) Percentage of mice free of diabetes upon 
treatment with Ig-GAD2 or the control Ig-HEL at the preinsulitis (C) and 
insulitis (D) stage, respectively. All mice were monitored for blood glucose 
from 12 to 30 wk of age. *, P   <   0.05; **, P   <   0.01 compared with untreated 
mice. A mouse is considered diabetic when blood glucose level is   ≥   300 
mg/dl for two consecutive weeks. An untreated group was included in all 
experiments for comparison purposes. At least 10 mice were included in 
each experimental group.     
    Figure 2.         Ig-GAD2 treatment given at the prediabetic stage re-
verses T1D.   (A and B) Percentage of mice free of diabetes upon treat-
ment with Ig-GAD2 or the control Ig-HEL at the hyperglycemic stage for 
15 (A) or 25 wk (B). Arrows indicate the beginning and end of treatment. 
(C and D) Individual blood glucose levels of Ig-GAD2 treated mice are 
shown from the week of diagnosis of hyperglycemia up to 52 or 56 wk of 
age for 15 (C) and 25 wk (D) treatment regimens. Each dot represents a 
different mouse. A mouse is considered hyperglycemic or diabetic when 
blood glucose level is between 160  –  250 or   ≥   300 mg/dl for two consecu-
tive weeks, respectively. The shaded area indicates the hyperglycemic 
range of blood glucose levels and the line depicts the diabetic level. 
An untreated group was included in all experiments for comparison purposes. 
At least 10 mice were included in each experimental group.     JEM VOL. 205, January 21, 2008 
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Ig-HEL recipient mice became diabetic by the fi  fth week of 
hyperglycemia. When the regimen was extended to 25 wk, 
100% of the Ig-GAD2  –  treated animals were protected (  Fig. 
2 B  ), and normoglycemia was restored in all mice. This status 
persisted throughout the duration of the study (mice aged 
52  –  56 wk). The weekly blood glucose level of individual 
mice shows a consistent pattern of return to normoglycemia 
for 6 out of 10 mice in the 15-wk treatment regimen, and 
all 10 animals in the 25-wk regimen (  Fig. 2, C and D  ). A 
detailed description of the day of onset, as well as the level of 
blood glucose at the beginning and termination of the hyper-
glycemic treatment regimen, is provided in Table I.   These 
results demonstrate that protection against the disease by Ig-
GAD2 occurs at the onset of insulitis, whether this manifests 
at an early or an older age. Overall, this antigen-specifi  c sin-
gle-epitope therapy by Ig-GAD2 restores normoglycemia 
in prediabetic mice, a stage at which GAD2-specifi  c T cells 
could be targeted. 
  Treatment with Ig-GAD2 increases the number of healthy 
pancreatic islets 
  To determine whether the restoration of normoglycemia 
by Ig-GAD2 is caused by interference with cell infi  ltration, 
the mice were subjected to histopathologic analysis upon 
diabetes (  16  ). Ig-GAD2 was then tested for delay of TID 
upon IAA-seroconversion. An initial regimen consisting of 
300   μ  g of Ig-GAD2 at week 1, 2, and 3 upon IAA serocon-
version indicated that 50% of mice were protected against 
diabetes up to 30 wk of age (unpublished data). This was 
promising, as the same regimen did not protect at the prein-
sulitis stage, and it prompted us to test a prolonged regimen 
for suppression of diabetes. As indicated in   Fig. 1 D  , adminis-
tration of Ig-GAD2 into insulitis-positive (IAA  +  ) mice de-
layed T1D, and most of the animals (7 out of 10) remained 
free of disease by week 30 of age. Ig-HEL  –  treated animals, 
like the untreated group, were not signifi  cantly protected 
(  Fig. 1 D  ). These results indicate that Ig-GAD2 protects 
against T1D at a later, rather than earlier, stage of the disease. 
We then evaluated Ig-GAD2 at the more advanced hypergly-
cemic stage. Accordingly, blood glucose levels were moni-
tored beginning at week 12 of age, and mice displaying 
hyperglycemia between the ages of 14 to 30 wk were sub-
jected to a daily injection of Ig-GAD2 for 5 d, and then a 
weekly injection for either 15 or 25 wk. The results show that 
90% of the mice under the 15-wk Ig-GAD2 regimen were 
protected against diabetes throughout the 15 wk of treatment 
(  Fig. 2 A  ).   However, only 60% of the mice remained disease-
free for the 10 wk after cessation of treatment. Untreated and 
    Table I.        Blood glucose (BG) level at the onset of hyperglycemia and at termination of treatment regimen    a   
Mouse ID Age at onset of hyperglycemia (wk) Blood glucose level before 
treatment (mg/dl)    b   
Blood glucose level after 
termination of treatment (mg/dl)    c   
15-wk treatment regimen
     106.1 30 161 133
     106.7 30 165 113
     119.2 30 180 285    d   
     119.8 26 182 112
     119.9 28 165 128
     190.1 12 250 118
     191.2 18 179 99
     192.2 26 212 134    d   
     192.3 16 160 308    d   
     196.1 22 222 150    d   
25-wk treatment schedule
     220.1 26 160 135
     221.12 24 174 120
     206.2 24 231 121
     203.1 24 181 110
     232.3 20 173 140
     236.6 14 185 116
     225.9 26 163 120
     237.8 20 250 130
     227.7 28 180 137
     244.4 16 171 123
  a    The results illustrated in this table were from the mice treated with either the 15- or 25-wk Ig-GAD2 treatment regimen and described in   Fig. 2  . The hyperglycemia onset 
represent the week during which the mice showed, for the fi  rst time, a blood glucose level of 160  –  250 mg/dl.
  b    Blood glucose level obtained the second week of hyperglycemia.
  c    Blood glucose level obtained at the termination of treatment regimen.
  d    Mice that became diabetic before or within 7 wk of treatment termination.210 TARGETING TH17 CELLS FOR REVERSAL OF TYPE I DIABETES | Jain et al.
vs. 22 and 31%, respectively). Surprisingly, in the 25-wk treat-
ment group, although the total number of islets was reduced 
to that of the hyperglycemic stage, most of these islets exhib-
ited no insulitis (60%), periinsulitis (28%), or mild intrainsu-
litis (12%;   Fig. 3 C  ). Overall, the treatment with Ig-GAD2 
led to a signifi  cant increase in the number of noninfl  amed 
(healthy) islets. 
  Ig-GAD2  –  treated mice exhibit pancreatic     -cell division 
  The increase in the number of healthy islets in the treated mice 
could be caused by regression of cell infi  ltration and/or for-
mation of new       cells. To address this premise, the treated mice 
were injected with the proliferation indicator BrdU and killed, 
and pancreatic sections were double stained with anti-insulin 
and -BrdU antibodies and analyzed for BrdU incorporation 
completion of the treatment regimen. As indicated in   Fig. 3  , 
most of the islets in hyperglycemic and diabetic mice exhibited 
intrainsulitis (  Fig. 3 A,   1, 2, and 3), the majority of islets in 
treated mice were not infl  amed (  Fig. 3 A,   4) or had only mild 
periinsulitis (  Fig. 3 A,   5 and 6).   Moreover, enumeration of 
the islets indicated that the treated animals had a signifi  cantly 
greater number of total islets than the hyperglycemic or dia-
betic mice (  Fig. 3 B  ). The number of insulin-positive islets 
also increased from 14 per pancreas at the prediabetic (hyper-
glycemic) stage to 29 per pancreas upon treatment with Ig-
GAD2. Also, the 15-wk group had a higher number of islets 
with periinsulitis (38 vs. 30%) or no insulitis (35 vs. 17%) rel-
ative to the hyperglycemic stage (  Fig. 3 C  ). On the other hand, 
the number of islets with severe and mild intrainsulitis were 
reduced in the treated versus hyperglycemic mice (8 and 19% 
    Figure 3.         Ig-GAD2 treatment diminishes insulitis and increases the total number of islets.   (A) Pancreatic histology. Four sections per pancreas 
(8      m thick each cut 100      m apart) from 5 hyperglycemic (A, 1 and 2), untreated diabetic (A, 3) or 15-wk Ig-GAD2  –  treated nondiabetic (A, 4, 5, and 6) mice 
were stained with hematoxylin and eosin and analyzed at 400  ×   magnifi  cation. For the hyperglycemic and untreated diabetic mice sections were made the 
second week of diagnosis. For the treated nondiabetic mice, histology was performed 7 wk after the last treatment. (B) Total islets per pancreas as deter-
mined by hematoxylin and eosin staining from the three groups of mice described in A. Only structures with visible islet cells and incomplete infi  ltration 
were counted. (C) Islets from hyperglycemic, 15 and 25 wk Ig-GAD2  –  treated mice were scored as described in Materials and methods, and the percent-
ages represent the number of islets of a given score over the total number of islets from B. The sections were made at the time indicated in A, and 2 d 
after the last Ig-GAD2 injection for the 25 wk  –  treated group. ***, P = 0.0001 for the total number of islets in 15 wk  –  treated versus hyperglycemic group. 
Error bars indicate the SD. Bars, 25     m.   JEM VOL. 205, January 21, 2008 
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recov  ery from the disease involved localized bystander sup-
pression. To test this premise, the splenic cells from recovered 
mice were stimulated with GAD2 peptide and assessed for both 
suppressive and infl  ammatory cytokines. The results indicate 
that although no measurable IL-4 or TGF      was detected (not 
depicted), there was signifi  cant IFN      and IL-10 production 
by these cells relative to the control HEL peptide (  Fig. 5 A  ).   
Moreover, intracellular cytokine analysis of CD4 and V     8.2 
and insulin production. BrdU staining was visible in the highly 
proliferative luminal intestinal cells used as control, but these 
had no staining with anti-insulin antibody (  Fig. 4 A  ).   Islets of 
nondiabetic 5-wk-old mice were positive for insulin, but did 
not incorporate BrdU, suggesting that these insulin-produc-
ing       cells were not dividing (  Fig. 4 B  ). Thus, under normal 
circumstances, insulin production emanates from existing 
      cells whose nuclei do not incorporate BrdU, giving a mini-
mal number of BrdU/insulin double-positive (BrdU  +  /insulin  +  ) 
      cells (  Fig. 4 E  ). The hyperglycemic mice showed very 
few insulin-producing       cells and no BrdU incorporation 
(  Fig. 4 C  ), resulting in an insignifi  cant number of BrdU  +  /
insulin  +   cells (  Fig. 4 E  ). In contrast, islets from the 25-wk treat-
ment group showed insulin  +         cells that were either BrdU         
(residual       cells) or BrdU  +   (newly formed       cells;   Fig. 4 D  ). 
Notably, the number of these insulin-producing dividing 
      cells was signifi  cantly increased in all 10 mice in which treat-
ment restored normoglycemia (  Fig. 4 E  ). Interestingly, the 
total number of dividing cells producing insulin (BrdU  +  /
insulin  +  ) was low, and it may not solely account for the restora-
tion of normoglycemia. BrdU        /insulin  +   residual islet cells, which 
amounted to 81 cells per pancreas, may have also contributed 
to the control of blood glucose levels, and these likely represent 
a combination of newly formed and residual       cells that 
were rescued by regression of infi  ltration. There was a mini-
mal number of dividing       cells (BrdU  +  /insulin  +  ) in the normal 
and hyperglycemic groups, despite the presence of 927 and 
50 BrdU        /insulin  +         cells, respectively. These results indicate 
that treatment with Ig-GAD2 reduces cell infi  ltration, leading 
to rescue of residual and formation of new       cells. 
  Ig-GAD2  –  treated mice produce protective IFN     
  Previous studies indicated that Ig-GAD1, which is an Ig chi-
mera carrying GAD524-543, and Ig-INS      carrying insulin 
9  –  23 aa residues induce T regulatory (T reg) cells and pre-
vent T1D only when given in an aggregated, but not soluble, 
form (  15, 16  ). This is because aggregated, but not soluble, Ig 
chimeras cross-link Fc     R on APCs, induce IL-10 by the pre-
senting cells, and expand T reg cells (  15, 16  ). In this study, 
only soluble Ig-GAD2 was used for treatment. Despite the 
fact that soluble Ig-GAD2 does not induce the production by 
APCs of the T reg cell growth factor IL-10 (  19  ) and is predicted 
not to expand T reg cells, it was tested for expansion of T 
reg cells in hyperglycemic mice before and after treatment 
with Ig-GAD2. The results indicated that the percentage of 
CD4  +  CD25  +  CD62L  +   and CD4  +  CD25  +  FoxP3  +   T cells in 
the spleen, as well as in the pancreatic lymph nodes, were 
similar before and after treatment (Table II).   This suggests 
that T reg cells play a minimal role in disease reversal by sol-
uble Ig-GAD2. 
  For Ig-GAD2 therapy, it is logical to contemplate that the 
resolution of the infl  ammatory infi  ltration is caused by mod-
ulation of GAD2-reactive diabetogenic T cells. Because T1D 
is likely to involve multiple autoantigens, the restoration of 
normoglycemia would require modulation of diverse T cell 
specifi  cities. Thus, the plausible hypothesis postulates that 
    Figure 4.              Cells from mice treated with Ig-GAD2 incorporate 
BrdU.   Mice (10 per group) were given 100 mg/kg BrdU i.p. and killed 3 h 
later. Sections of the small intestine or pancreas were stained with anti-
insulin and -BrdU antibodies, and then analyzed for insulin production 
(blue cytoplasmic rim) and BrdU incorporation (red nuclei) at 400  ×   mag-
nifi  cation. Blue arrows indicate BrdU  +   cells, green arrows indicate insulin  +  
cells, and red arrows indicate BrdU  + /insulin +   cells. Intestinal lumen (A) and 
      cells (D) from mice recipient of the 25-wk Ig-GAD2 regimen. (B) Beta 
cells from 5-wk-old nondiabetic NOD mice. (C)       Cells from hyperglyce-
mic mice. (E) Total number of insulin  + /BrdU +   cells in nondiabetic (normal), 
hyperglycemic, and Ig-GAD2  –  treated nondiabetic NOD mice. ***, P = 
0.0001, treated group compared with hyperglycemic group. Error bars 
indicate the SD of 10 pancreata. Bars: (A  –  C) 25      m; (D, left) 20     m; 
(D, right) 5     m  D.   212 TARGETING TH17 CELLS FOR REVERSAL OF TYPE I DIABETES | Jain et al.
with anti  –  IL-10 treatment, but was nullifi  ed by removal of 
IFN      (  Fig. 5 C  ). Isotype-matched rat IgG had no eff  ect on the 
disease (  Fig. 5 C  ). These observations indicate that IFN     , 
contrary to its well-defi  ned infl  ammatory function, is likely 
involved in modulation of inflammation and restoration 
of normoglycemia. 
  Ig-GAD2 treatment interferes with IL-17 production 
in an IFN    -dependent fashion 
  Th17 cells represent a newly defi  ned subset of pathogenic 
T cells whose development can be facilitated by TGF      and 
T cells indicated that the majority of the T cells produced 
only IFN     , with fewer cells stained positive for both IL-10 
and IFN      (  Fig. 5 B  ). Indeed, upon stimulation with GAD2 
peptide, a signifi  cant increase (four- to sevenfold) in the number 
of CD4/V     8.2 T cells producing IFN      was observed in the 
Ig-GAD2  –  treated versus untreated mice. Because IL-10 is 
known for its anti-Th1 suppressive function (  20  –  22  ), we sus-
pected that protection against the disease involves the func-
tion of these IL-10/IFN      –  producing cells. To our surprise, 
however, when in vivo cytokine neutralization was per-
formed along with Ig-GAD2 treatment, the recovery persisted 
    Table II.        Reversal of T1D by Ig-GAD2 does not signifi  cantly increase expression of phenotypic markers associated with T reg cells    a   
CD4  +  CD25  +  FoxP3  + CD4  +  CD25  +  CD62L  + 
Untreated Treated Untreated Treated
SP 4.9 3.3 2.0 1.9
PLN 5.0 5.5 3.0 4.4
  a    Spleen and pancreatic lymph node cells from Ig-GAD2  –  treated and control untreated mice were stained with anti-CD4, -CD25, and -CD62L or -FoxP3 antibody. The cells were 
gated on CD4  +   cells and analyzed for CD25, FoxP3, and CD62L expression by fl  ow cytometry.
    Figure 5.         Treatment with Ig-GAD2 induces IFN     that sustains protection against diabetes.   (A) Splenocytes from hyperglycemic mice recipient of 
the 25-wk Ig-GAD2 treatment regimen were stimulated in vitro with GAD2 and the control HEL peptide and IFN      and IL-10 were measured by ELISA as 
described in Methods. Diabetic as well as untreated hyperglycemic mice were included for control purposes. Each bar represents the mean   ±   SD of three 
independent experiments. *, P = 0.01 when stimulation by GAD2 is compared with HEL peptide. (B) Intracellular IL-10 and IFN      production by splenic CD4 
(top) or V     8.1/8.2 (bottom) T cells from the 25-wk  –  treated (right) and hyperglycemic untreated (left) mice. This was done by intracellular staining upon 
stimulation with GAD2 peptide, as indicated in the Materials and methods. Data are representative of three independent experiments. (C) Percentage of 
mice free of diabetes upon in vivo neutralization of IFN      (left) or IL-10 (right) during treatment with Ig-GAD2 at the hyperglycemic stage. Anti-IFN      (R4-
6A4), anti-IL-10 (JES5-2A5), or isotype control rat IgG were given to mice (500   μ  g/mouse per injection) i.p. every 3 d for 4 consecutive weeks, beginning 
with the fi  rst injection of Ig chimeras. The mice received a total of nine antibody injections. At least eight mice were included in each experimental group.     JEM VOL. 205, January 21, 2008 
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IL-6 or interfered with by IFN      or IL-27 (  9, 10, 23  –  26  ). 
Because Ig-GAD2 treatment induces IFN     , we sought to 
determine whether restoration of normoglycemia involves 
interference with IL-17 production. Accordingly, we began 
by assessing whether IL-17 is produced by NOD T cells, and 
followed the pattern of its secretion during disease progres-
sion.   Fig. 6 A   shows that stimulation with anti-CD3 antibody 
did not induce measurable IL-17 by splenocytes from normal 
4-wk old mice. However, IL-17 was evident upon IAA-sero-
conversion and increased signifi  cantly when the mice pro-
gressed to hyperglycemia and diabetes. The treatment with 
Ig-GAD2 at the hyperglycemic stage signifi  cantly reduced 
the frequency of GAD2-specifi  c IL-17  –  producing cells as 
measured by spot formation (  Fig. 6 B  ).   However, neutraliza-
tion of IFN      by administration of anti-IFN      antibody along 
with Ig-GAD2 restored even higher frequency of Th17 cells. 
This Th17 restoration is likely caused by complete neutral-
ization of IFN      because IFN     -producing Th1 cells could 
not be detected by ELISPOT (not depicted) and no measur-
able IFN      cytokine was found by ELISA (  Fig. 6 C  ). It is thus 
likely that the restoration of diabetes by neutralization of 
IFN      during treatment with Ig-GAD2 (  Fig. 5 C  ) is caused by 
restoration of Th17. In fact, administration of rIL-17 along 
with Ig-GAD2 treatment nullifi  es tolerance and restores dia-
betes (  Fig. 6 D  ). Moreover, administration of both anti-IFN      
and   –  IL-17, but not anti-IFN      and rat IgG, simultaneously 
protects against T1D (  Fig. 6 D  ), further confi  rming the inter-
play between IFN      and IL-17. To ensure that Th17 cells can 
be diabetogenic, we chose the BDC2.5 TCR transgenic T cells 
(  27  ) for polarization with anti-CD3 and -CD28 antibodies 
and tested for transfer of diabetes into NOD.scid mice. The 
rationale for this choice instead of Ig-GAD2  –  induced Th17 
cells lies in the fact that the BDC2.5 cells are well character-
ized and represent a homogeneous population in which the 
number of cells to be transferred can be precisely controlled. 
In addition, the Ig-GAD2/NOD model represents a polyclonal 
system in which the diff  erent subsets of T cells cannot be 
separated. Thus, BDC2.5 T cells were stimulated with anti-CD3 
and -CD28 antibodies in the presence or absence of Th17 
polarizing factors, and the cells were tested for transfer of dia-
betes into NOD.scid mice. 
  As indicated in   Fig. 6 E  , the Th17-polarized cells had en-
hanced levels of IL-17 compared with nonpolarized cells, but 
no measurable IFN     , whereas nonpolarized cells produced 
signifi  cant IFN     . These results indicate that the polarization to 
Th17 was signifi  cant under the chosen conditions. Further-
more, when the polarized cells were transferred into NOD.scid 
mice, diabetes manifested within 16 d after transfer, as with 
activated, but not polarized, T cells (  Fig. 6 F  ). Diabetes did not 
occur when the transfer was made with naive BDC2.5 cells. In 
addition, when IL-17 was neutralized by injection of anti  –  IL-17 
    Figure 6.         Neutralization of IFN     during treatment with Ig-GAD2 
restores IL-17 production.   (A) IL-17 response from the splenocytes of 
preinsulitis (normal), insulitis-positive (IAA  +  ), hyperglycemic, and diabetic 
mice upon in vitro stimulation with anti-CD3 antibody. Data are represen-
tative of three independent experiments. ***, P = 0.0004, insulitis-positive 
versus normal; *, P = 0.02, hyperglycemic versus insulitis-positive; **, P = 
0.005, diabetic versus hyperglycemic group. IL-17 (B) and IFN      (C)  re-
sponse from splenocytes of mice recipient of anti-IFN      during  treatment 
with Ig-GAD2 at the hyperglycemic stage. Splenocytes were harvested 
when the mice became diabetic on the fourth week of treatment; they 
were stimulated in vitro with GAD2 peptide, and their responses were 
measured by ELISPOT and ELISA, respectively. Nil (diabetic) and Ig-GAD2  –
  treated groups were included as controls. Data are representative of three 
independent experiments.   †  , P = 0.01, treated versus nil group;   †    †  , P = 
0.001, Ig-GAD2 + anti-IFN      versus Ig-GAD2 group.   †  , P = 0.04, Ig-GAD2 
versus nil group;   †  , P = 0.02, Ig-GAD2 + anti-IFN      versus Ig-GAD2 group. 
(D) Percentage of mice free of diabetes upon administration of recombi-
nant IL-17 or neutralization of both IFN      and IL-17 during treatment 
with Ig-GAD2 at the hyperglycemic stage. IL-17 was administered (1   μ  g/
mouse per injection) i.p. daily for 5 consecutive days, beginning with the 
fi  rst injection of Ig-GAD2. Subsequently, the mice received an injection 
of rIL-17 every week, along with Ig-GAD2. An injection of anti-IFN     
(R4-6A4; 500   μ  g/mouse) and anti-IL-17 (TC11-18H10; 200   μ  g/mouse) was 
given on the first day of treatment with Ig-GAD2 after diagnosis of 
hyperglycemia. Four additional injections were given at 4-d intervals. 
At least eight mice were included in each experimental group. (E and F) Th17-
polarized cells induce diabetes. (E) IL-17 (left) and IFN      (right)  responses 
from the nonpolarized and Th17 polarized splenocytes were measured 
by ELISA. Each bar represents the mean   ±   SD of triplicate wells. (F) 
Percentage of mice free of diabetes upon adoptive transfer of 10   ×   10  6  
naive, nonpolarized and Th17-polarized cells in NOD.scids (4  –  6 wk old). 
Additional groups received IL-17 neutralizing antibody, along with Th17-
polarized and nonpolarized cells for control purposes. Anti  –  IL-17 antibody 
(TC11-18H10; 200   μ  g/mouse) was given on the day of transfer, and two 
additional injections were given at day 4 and 16 after transfer.     
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the 25-wk regimen and all animals maintained normoglyce-
mia until they were terminated at 52 or 56 wk of age for 
other use. At the histology level, the 15-wk regimen reduced 
infi  ltration, and this was accompanied by an increase in the 
total number of islets relative to the beginning of the treat-
ment (  Fig. 3 B  ). However, with the 25-wk regimen, the 
number of islets dropped back to where it was at the hyper-
glycemic stage, but the majority of these were healthy islets. 
We believe that both eradication of infi  ltration from slightly 
infi  ltrated islets as well as formation of new islets were part of 
the repair process. The initial increase and the return of the 
number of islets may refl  ect dynamics in which new islets 
were formed while severely infi  ltrated islets were eliminated 
and those mildly infi  ltrated were cleaned up. This is drawn 
from   Fig. 3 C  , which illustrates the evolution of status and 
number of islets during the treatment and is supported by the 
BrdU incorporation observed with insulin-producing       cells 
(  Fig. 4  ). There was, in fact, a substantial increase of dividing 
cells that were simultaneously producing insulin, in addition 
to cells that were producing insulin without evidence of divi-
sion (  Fig. 4  ). The formation of new islets has been reported 
before, but whether these are the product of stem cells matu-
ration, origination from splenic cells, or division of residual 
      cells remains unknown (  34  –  38  ). It has been shown that phys-
ical damage of islets stimulates       cell division (  38  ). In Ig-
GAD2  –  treated mice, upon clearance of infl  ammatory cells the 
damaged islets may likewise spontaneously initiate division of 
      cells. However, given that exogenous compounds such as 
CFA (  35  –  37  ) and now Ig-GAD2 allow for       cell division, it may 
be that clearance of infl  ammatory cells minimizes cell divi-
sion inhibitory factors, leading to proliferation of residual       
cells or diff  erentiation of       cell progenitors. The precise mecha-
nism underlying       cell proliferation is of great interest, and 
antibody in the mice recipient of Th17-polarized cells, the 
disease did not manifest. However, neutralization of IL-17 did 
not protect against diabetes transferred by nonpolarized cells. 
These results indicate that Th17 cells producing IL-17 can 
transfer diabetes into naive mice. The results are thus inter-
preted to indicate that Ig-GAD2 mobilizes IFN     -producing 
splenic Th1 cells that interfere with IL-17  –  producing diabeto-
genic lymphocytes to reduce infl  ammation, sustain islet for-
mation, and restore normoglycemia. 
  Treatment with Ig-GAD2 sustains long-lasting production 
of IFN     in the spleen and nullifi  es IL-17 in the pancreas 
  At the hyperglycemic stage, most of the pathogenic T cells 
likely reside in the pancreas as diff  erentiated cells that have 
already been exposed to antigen (  28, 29  ). Because IFN      has 
been suggested to interfere with the diff  erentiation of naive 
cells into Th17 (  9, 10  ), it is likely that IFN      Th1 cells operate 
their interference with Th17 in the spleen or pancreatic 
lymph nodes rather than the pancreas. Analysis of the dynam-
ics of both populations at the beginning, as well as at the end, 
of Ig-GAD2 treatment indicated that during the initial phase 
of hyperglycemia, IFN     -producing Th1 cells are mostly lo-
cated in the spleen (  Fig. 7 A  ), whereas Th17 cells reside in 
the pancreas (  Fig. 7 B  ).   However, at the end of the treatment, 
Th1 cells remain in the spleen (  Fig. 7 C  ), whereas Th17 cells are 
undetectable in any organ (  Fig. 7 D  ). These results suggest that 
Ig-GAD2 induces IFN      in the spleen, which likely interfere 
with diff  erentiation of naive cells into Th17 cells, resulting in a 
diminished supply of these cells to the pancreas. 
    DISCUSSION   
  Treatment with anti-CD3 antibody alone has been shown to 
reverse diabetes, but disease reoccurrence has been observed 
(  30  –  32  ). This justifi  es the search for new strategies, and the 
combination of anti-CD3 antibody with antigen-specifi  c 
therapy did overcome rebounding of disease (  33  ). Because T1D 
involves multiple autoantigens that likely manifest their activities 
at diff  erent stages of the disease, it has been diffi   cult to defi  ne 
antigen-based regimens that could reverse the disease process 
at an advanced stage (  1  ). Because Igs have proven powerful for 
enhancing tolerogenic function of peptides (  12, 16  ) and GAD2 
peptide was defi  ned as a late-stage protective epitope (  5  –  8  ), 
we incorporated GAD2 peptide onto an Ig molecule and 
tested the resulting Ig-GAD2 for protection, as well as reversal 
of advanced T1D process. Surprisingly, Ig-GAD2 was not 
protective at the preinsulitis stage (  Fig. 1 C  ), but delayed the 
disease when it was administered upon IAA seroconversion 
(  Fig. 1 D  ) (  14  ). This diff  erential effi   cacy may be related to de-
layed spreading of GAD2-specifi  c T cells that become available 
for targeting at an advanced stage of the disease (  7  ). This 
has prompted us to test for reversal of T1D at the prediabetic 
stage, when blood glucose has reached an abnormal level. 
Again, Ig-GAD2 was able to restore long-lasting normo-
glycemia in most of the animals (  Fig. 2, A and C  ), and when the 
regimen was extended to 25 wk (  Fig. 2, B and D  ) all mice 
were protected. To date, we have tested   >  30 mice with 
    Figure 7.         Splenic IFN     induced by Ig-GAD2 treatment diminishes 
splenic and pancreatic IL-17 causing reversal of diabetes.   IFN     and 
IL-17 cytokine responses of splenic, pancreatic, and pancreatic lymph 
node cells from mice treated with Ig-GAD2 for 1 wk (A and B) or 25 wk 
(C and D) starting from the week of hyperglycemia diagnosis. The cells were 
stimulated with GAD2 peptide, and the responses were measured by ELISA 
for IFN      and ELISPOT for IL-17, as indicated in Materials and methods. 
Each bar represents the mean   ±   SD of two independent experiments.     JEM VOL. 205, January 21, 2008 
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In fact, this goes well with the observation that neutralization of 
IL-17 did not protect against diabetes transferred by IFN     -
producing Th1 BDC2.5 cells, as these lymphocytes could 
home to the pancreas, where their IFN      drives apoptosis of 
      cells (  Fig. 6, E and F  ). 
  Overall, we suggest that adjuvant-free Ig-GAD2 induced 
the production of IFN      in a noninfl  amed lymphoid organ, 
leading to inhibition of diff  erentiation of naive cells into Th17 
cells, culminating in diminished infi  ltration, formation of       
cells and reversal of the diabetic process. The presence of IFN      
would inhibit diff  erentiation of neighboring naive cells, thus 
suppressing diverse T cell specifi  cities. For eff  ective bystander 
suppression to occur, it may be that Th1 cells migrate to the 
PLN and inhibit diff  erentiation of diverse T cells into Th17 
cells. However, because Th1 cell were not detected in this 
organ, the likely alternative is that APCs loaded with      -cell 
antigens circulate from the pancreas to the spleen and subject 
diverse T cells to inhibition of diff  erentiation by local IFN     -
producing GAD2-specifi  c Th1 cells. Administration of exog-
enous IFN      may protect against diabetes if targeted to the 
site of T cell diff  erentiation during antigen stimulation, but 
away from the islets. It is also important to mention that the 
regimen is eff  ective at late stages, but not before insulitis, pos-
sibly because availability of GAD2-specifi  c T cells and pro-
duction of IFN      are delayed. In fact, Ig-INS      was able to 
delay the disease when given at the preinsulitis stage (  16  ), but was 
unable to counter the disease once the mice had progressed 
to the hyperglycemic stage (not depicted). Again, this supports 
the dynamics of diff  erent epitopes during disease initiation 
and progression. 
  Collectively, the fi  ndings suggest that this antigen-specifi  c 
immunomodulation targets diverse pathogenic T cells to halt 
infl  ammation and drive an islet repair process that restores 
long-lasting normoglycemia. 
    MATERIALS AND METHODS   
  Mice 
  NOD (H-2  g7  ), NOD.BDC2.5, and NOD.scid mice were used according 
to the guidelines of the University of Missouri Columbia Animal Care and 
Use Committee. 
  Peptides 
  All peptides used in this study were purchased from Metabion and purifi  ed by 
HPLC to   >  90% purity. Glutamic acid decarboxylase 2 (GAD2) peptide corre-
sponds to aa residues 206  –  220 (TYEIAPVFVLLEYVT) of GAD-65 (  7  ). Hen 
egg lysozyme (HEL) peptide encompasses a nondiabetogenic epitope corre-
sponding to aa residues 11  –  25 (AMKRHGLDNYRGYSL) of HEL (  43  ). 
GAD2 and HEL peptides are presented to T cells in association with I-A  g7   
MHC class II molecules. 
  Ig chimeras 
  Ig-GAD2 and Ig-HEL express GAD2 and HEL peptide, respectively. This 
was accomplished by inserting the corresponding nucleotide sequence in 
place of the diversity segment within the complementarity determining re-
gion 3 (CDR3) of the heavy chain variable region of the 91A3 IgG2b,       Ig 
(  13  –  16  ). The fusion heavy chain gene was then transfected along with the 
parental       light chain gene for expression as a complete self-Ig molecule, 
as previously described (  11, 13  –  16  ). Large-scale cultures of transfectoma 
cells were performed in DME media containing 10% iron-enriched calf 
eff  ort is being made to determine how Ig-GAD2 leads to       
cell division. What is important here is that a single-epitope 
treatment could lead to eradication of infi  ltration involving 
diverse T cell specifi  cities. One has to assume that there must 
be at least a local bystander suppression that targets GAD2-
specifi  c T cells and unrelated neighboring cells. When the mice 
treated with Ig-GAD2 were tested for cytokine production, 
we expected to see suppressive or Th2-associated cytokines, 
which usually drive bystander suppression. The results, how-
ever, showed that there was IL-10 production, but that this was 
accompanied by IFN      (  Fig. 5  ). The other surprise was that 
neutralization of IFN     , but not IL-10, nullifi  es the therapeutic 
action of Ig-GAD2 and restores diabetes (  Fig. 5  ). These fi  ndings 
provide support to prior observations showing that TCR trans-
genic IFN     -producing GAD2-specifi  c T cells prevent the onset 
of diabetes in an animal model of disease transfer (  8  ). The 
question then is how can a well-defi  ned infl  ammatory cyto-
kine such as IFN      mediate suppression of diabetes, which 
likely involves diverse T cell specifi  cities? Given the recent 
observations indicating that IFN      could interfere with diff  er-
entiation of naive cells into Th17 (  9, 10  ), and that IL-17, which 
is the product of Th17, displays pathogenic functions (  39  ), 
we sought to test whether progression to diabetes involves 
the activity of Th17 and if so whether treatment with Ig-GAD2 
aff  ects these pathogenic T cells. Indeed, an increase of IL-17 
was observed in NOD mice as they progressed toward dia-
betes (  Fig. 6 A  ), and treatment with Ig-GAD2 reduced the 
frequency of IL-17  –  producing Th17 cells (  Fig. 6 B  ). However, 
neutralization of IFN      by anti-IFN      antibody restored IL-17 
production (  Fig. 6 B  ). In support of this Ig-GAD2  –  induced 
IFN     /IL-17 interplay is the observation that administration 
of rIL-17 with Ig-GAD2 nullifi  ed the therapeutic eff  ect of 
Ig-GAD2. Also, neutralization of both IFN      and IL-17 sup-
port protection, further justifying the IFN     /IL-17 interplay. 
Moreover, polarized BDC2.5 Th17 cells transferred diabetes 
to NOD.scid mice, and neutralization of IL-17 inhibited 
such disease transfer (  Fig. 6 F  ). Finally, IFN      is mostly pro-
duced in the spleen, which provides a noninfl  ammatory envi-
ronment ( Fig. 7, A and B ) and likely acts to inhibit diff  erentiation 
of naive cells into Th17 in this organ, leading to a diminished 
supply of pathogenic Th17 cells into the pancreas. In fact, upon 
treatment with Ig-GAD2, Th17 cells become undetectable in 
the spleen or pancreas, whereas IFN      remained signifi  cant in 
the spleen to sustain a long-lasting inhibition of Th17 diff  er-
entiation (  Fig. 7, C and D  ). It is known that IFN      signaling 
through IFN      receptor (IFN     R), in conjunction with other 
infl  ammatory cytokines, interferes with       cell growth and in-
duces apoptosis (  40, 41  ). In the Ig-GAD2 treatment, the fact that 
IFN      is produced in the spleen may play dual benefi  cial roles. 
It inhibits diff  erentiation of pathogenic Th17 cells, allowing 
for clearance of infi  ltration and termination of islet infl  amma-
tion and by being away from the islets its interference with 
      cell growth and death is prevented, hence proliferation of 
      cells. This also provides support to the dual pathogenic/
protective role IFN      plays in diabetes, which likely depends 
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anti  –  guinea pig antibodies, and visualized by saturation with Streptavidin-
alkaline phosphatase using the chromagen, 5-Bromo-4-chloro-3-indolyl 
phosphate/Nitroblue tetrazolium. For detection of BrdU incorporation, the 
sections were counter stained with biotinylated anti-BrdU antibody (Zymed), 
treated with Streptavidin-horseradish peroxidase, and visualized with the 
chromagen 3-amino-9-ethylcarbazole. 
  Cytokine assays 
  Splenocytes (5   ×   10  5   cells/well) were incubated with 30   μ  g/ml of free pep-
tide or 5   μ  g/ml anti-CD3 antibody for 48 h, and cytokines in the supernatant 
were measured by ELISA and ELISPOT, as previously described (  45  ). 
  Flow cytometry 
  For staining of CD4, CD25, and CD62L, cells were harvested from spleens 
and pancreatic lymph nodes and incubated with anti-CD4-PE, biotin-
conjugated anti-CD25 (or isotype control biotin-conjugated rIgM), and 
anti-CD62L-FITC (or isotype control rIgG2a-FITC) for 30 min at 4  °  C. 
Subsequently, the cells were washed and stained with PerCP-conjugated 
streptavidin for 30 min at 4  °  C. The cells were washed, fi  xed with 4% form-
aldehyde for 20 min at room temperature, and then analyzed. All antibodies 
were purchased from BD PharMingen. 
  For intracellular Foxp3 staining, cells from spleens and pancreatic lymph 
nodes were fi  rst stained with anti-CD4-PE and biotin-conjugated anti-CD25 
antibodies. This was followed by PerCP-conjugated streptavidin staining. 
The cells were fi   xed with Fix/Perm buff   er (eBioscience), washed with 
permeabilization buff  er (eBioscience), and stained with anti-Foxp3-FITC 
antibody (clone FJK-16s; eBioscience), or isotype control rIgG2a-FITC. 
  For intracellular cytokine analysis of IL-10 and IFN     , the splenic cells 
(2   ×   10  6   cell/ml) were stimulated with free peptide (30   μ  g/ml) for 6 h 
followed by 10 h incubation with brefeldin A (10      g/ml) to block cyto-
kine secretion and facilitate intracellular accumulation. The antibodies used 
were PerCP-anti-CD4 (RM4-5), biotin-anti-V     8.1/8.2, PE-anti-IFN      
(XMG1.2), and FITC-anti-IL-10 (JESS-16E3; all from BD Biosciences). 
Isotype-matched controls were included in all experiments. Events were 
collected on a FACScan fl  ow cytometer and analyzed with CellQuest soft-
ware (Becton Dickinson). 
  T cell polarization 
  Naive splenocytes were isolated from 4-wk-old NOD.BDC2.5 transgenic 
mice and activated with soluble anti-CD3 (5      g/ml) and anti-CD28 (5      g/ml) 
antibodies for 3 d in 10% FCS-DME media under Th17 polarizing (TGF      
[3 ng/ml], IL-6 [20 ng/ml], anti-IFN      antibody [10      g/ml], and anti  –  IL-4 
antibody [10      g/ml]) and nonpolarizing conditions. Supernatant from acti-
vated cells was tested for IFN      and IL-17 by ELISA, and the cells were used 
for adoptive transfers. 
  Adoptive transfer experiments 
  For disease transfer by Th17, 10   ×   10  6   naive, nonpolarized and Th17-polarized 
cells were injected i.v into NOD.scid (4  –  6-wk-old) mice. Additional groups 
of mice received IL-17  –  neutralizing antibody along with the T cell transfer 
to serve as controls. Anti-IL-17 antibody (TC11-18H10; 200   μ  g/mouse) 
was given on the day of transfer, and 2 additional injections were given at day 4 
and 16 after transfer. 
  Statistical analysis 
  The        2   test was used for incidence of diabetes analysis among experimental 
and control groups. For the rest of the experiments, P values were calculated 
with the two-tailed Student  ’  s unpaired   t   test. 
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serum (BioWhittaker). Purifi  cation of the chimeras used separate columns of 
rat anti  –  mouse       chain mAb coupled to CNBr-activated 4B Sepharose 
(GE Healthcare). 
  Islet cell purifi  cation 
  This was done according to a standard islet purifi  cation procedure (  44  ). 
In brief, the pancreata were digested with collagenase type IV (Invitrogen), 
and islets were separated on a fi  coll gradient (GE Healthcare). 
  T cell line and proliferation assay 
  A T cell clone specifi  c for GAD2 peptide was generated in NOD mice as 
previously described (  15  ). For presentation of Ig-GAD2, irradiated (3,000 
rads) NOD female splenocytes (5   ×   10  5   cells/50      l/well) were incubated 
with graded amounts of either free peptide or Ig chimeras (100   μ  l/well), and 
1 h later the GAD2-specifi  c T cells (5   ×   10  4   cells/well/50   μ  l) were added. 
Proliferation was measured by [  3  H]thymidine incorporation assay. 
  Assessment of insulin autoantibody (IAA) seroconversion, 
hyperglycemia, and diabetes 
  Serum IAA was detected by ELISA using porcine insulin as antigen, as previ-
ously described (  16  ). Assessment of blood glucose levels used test strips and 
an Accu-Chek Advantage monitoring system. A mouse is considered hyper-
glycemic or diabetic when the blood glucose level is 160  –  250 mg/dl or 
300 mg/dl, respectively, for 2 consecutive weeks. 
  Ig-GAD2 treatment regimens 
  Treatment at the preinsulitis stage.     Mice are given an i.p. injection of 
300   μ  g Ig-GAD2 or Ig-HEL in 300   μ  l PBS at 4, 5, and 6 wk of age, a stage 
at which islet infi  ltration has begun and that is referred to as preinsulitis. The 
mice were monitored for blood glucose level up to 30 wk of age. 
  Treatment at the insulitis (IAA  +  ) stage.     Mice are tested for IAA, and 
those who seroconvert between the ages of 8  –  11 wk are given a weekly i.p. 
injection of 300   μ  g of Ig-GAD2 or Ig-HEL in 300   μ  l PBS up to week 12. 
Subsequently, the mice received another 300   μ  g of Ig-chimera every 2 wk 
until the age of 24 wk. These mice were monitored for blood glucose level 
beginning at week 12 until 30 wk of age. 
  Treatment at the hyperglycemic stage.     Mice began blood glucose level 
monitoring at 12 wk of age, and those who displayed a level of 160  –  250 
mg/dl for 2 consecutive weeks between the ages of 14  –  30 wk were consid-
ered hyperglycemic. These mice were then subjected to a daily i.p. injection 
of 500   μ  g Ig-GAD2 or Ig-HEL for 5 d. Subsequently, the mice received an-
other 500   μ  g of Ig-chimera every week for 15 or 25 consecutive weeks, and 
blood glucose levels were continuously monitored until 56 wk. These treat-
ments are referred to as 15- and 25 wk-treatment regimen, respectively. 
  Histology 
  Pancreata were harvested from NOD females, fi  xed in 10% formalin, and 
embedded in paraffi   n. Sections of 8-     m thickness were cut 100      m apart to 
prevent double counting the same islet. Four sections per pancreas were 
stained with hematoxylin and eosin and analyzed by light microscopy. Insu-
litis scoring was performed according to the following criteria: severe insuli-
tis, 50% or higher of the islet area is infi  ltrated; mild insulitis,   <  50% of the 
islet area is infi  ltrated; periinsulitis, infi  ltration is restricted to the periphery 
of islets; and no insulitis, absence of cell infi  ltration. 
  Immunohistochemistry 
  Evaluation of cell division by insulin-producing       cells was done as follows: 
Ig chimera  –  treated mice were injected i.p. with 100 mg/kg of BrdU in PBS 
(Sigma-Aldrich), 3 h before euthanasia. Pancreata and intestine were har-
vested and fi  xed, and sections were prepared as described in the previous 
section. For assessment of insulin production, the sections were stained with 
primary guinea pig anti-insulin antibodies, incubated with biotinylated goat JEM VOL. 205, January 21, 2008 
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